Tratamiento farmacológico antiinflamatorio no esteroide oral para la fibrosis quística
Information
- DOI:
- https://doi.org/10.1002/14651858.CD001505.pub2Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 17 October 2007see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Cystic Fibrosis and Genetic Disorders Group
- Copyright:
-
- Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
Anna Crighton had the original idea for the review, drafted the protocol, extracted data and co‐authored the review. Carol Dezateux drafted the protocol and data extraction forms, extracted and analyzed data and was responsible for writing the review.
Anna Crighton and Carol Dezateux stepped down from the review as from February 2006.
Larry Lands took over as lead reviewer in May 2004. He led on the update of the review and acts as guarantor of the review.
Sanja Stanojevic joined the review in June 2006. She extracted and analyzed data for the subsequent updates and co‐authored the review.
Sources of support
Internal sources
-
Institute of Child Health, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
External sources
-
Tenovus, Scotland, UK.
Declaraciones de interés
Dr Larry Lands fue el investigador principal en el Ensayo transcanadiense (Lands 2007)).
Agradecimientos
Se agradece al profesor Ros Smyth, a Jill Motley, a Nikki Jahnke y al Grupo Cochrane Editorial de Fibrosis Quística y Trastornos Genéticos (Cochrane Cystic Fibrosis and Genetic Disorders Editorial Group) por su apoyo valioso; a la profesora Carol Dezateux y a Anna Crighton por sus aportaciones a las versiones anteriores de esta revisión; al Dr. Michael Konstan por sus observaciones útiles sobre un borrador anterior de la revisión original; y al Dr. Somnath Mukhopadhyay por su estímulo.
Version history
| Published | Title | Stage | Authors | Version |
| 2019 Sep 09 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
| 2016 Apr 07 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
| 2013 Jun 13 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
| 2007 Oct 17 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
| 1999 Apr 26 | Oral non‐steroidal anti‐inflammatory drug therapy for cystic fibrosis | Review | Larry C Lands, Carol Dezateux, A Crighton, Sanja Stanojevic | |
Differences between protocol and review
There was a post‐hoc subgroup analysis of the lung function data split by age (two groups: 'under 13 years at randomisation' and '13 years and over at randomisation').
